Skip to content

The ROS1ders

Bridging ROS1+ Cancer Patients To Research

Menu
  • ABOUT ROS1
    • Drugs to Treat ROS1+ Cancer
    • Clinical Trials for ROS1+ Patients
    • ROS1 Experts
  • BLOG
  • PROJECTS
    • The ROS1 Cancer Model Project
  • RESOURCES
  • ABOUT US
  • CONTACT US

Why I advocate

Posted on September 12, 2015September 15, 2015Author grayconnectionsCategories Lysa BuonannoTags advocacy

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to share on WhatsApp (Opens in new window)
  • Click to print (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Reddit (Opens in new window)
  • Click to email this to a friend (Opens in new window)

Like this:

Like Loading...

Post navigation

Previous Previous post: Just keeps shrinking!
Next Next post: Small But Mighty: ROS1ers Unite

Follow Blog via Email

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 1,357 other subscribers

Tags

advocacy ASCO18 brain metastasis cancer models clinical trial Clinical trials community crizotinib diagnosis education Entrectinib G2032R IASLC Webinar Lung cancer Lung Cancer Canada Lungenkrebs mechanisms of resistance Newsletters NICE patient-driven research regulatory approval research results ROS1 ROS1 Cancer ROS1 testing RXDX-101 Side effects support survey survivorship testing guidelines The ROS1ders TPX-0005 UK Xalkori

ROS1 Cancer Research Forum on Facebook

ROS1 Cancer Research Forum on Facebook

ROS1 Social Media

  • View ROS1 Cancer Research Forum’s profile on Facebook
  • View @ros1cancer’s profile on Twitter

Blog Stats

  • 108,554 hits
Powered by WordPress.com.
  • ROS1 Cancer Facebook Group
  • @ros1 on twitter
  • ROS1 on LinkedIn
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
%d bloggers like this: